据京沪深交易所披露，上周（11月17日-11月21日）5家企业上会，新增2家新受理企业；5家提交IPO注 册申请，2家IPO注册获通过，4只新股上市。 振石股份主要从事清洁能源领域纤维增强材料的研发、生产及销售，主要产品包括清洁能源功能材料及 其他纤维增强材料。报告期内，振石股份关联采购占比较高，公司向第一大供应商中国巨石采购玻璃纤 维等的金额占营业成本的比例约6成，同时公司与中国巨石还存在采购电力、关联销售、关联租赁等一 般关联交易。 一、IPO审核与注册进展 审5过5，振石股份拟募资近40亿元 上周，5家IPO首发上会获通过。其中，振石股份拟登陆沪市主板，易思维拟登陆科创板，爱得科技、 通领科技、兢强科技拟在北交所上市。 审议会议现场，上市委重点问询该事项，要求公司结合向中国巨石采购玻璃纤维的定价依据、决策程 序、向第三方采购价格、中国巨石向第三方销售价格等，说明其与中国巨石关联交易的公允性；结合关 联方采购价格、采购比例、原材料客户认证要求等，说明公司是否存在对中国巨石的重大依赖。 此次IPO，振石股份计划募集资金39.81亿元，分别投向玻璃纤维制品生产基地建设项目、复合材料生产 基地建设项目、西班牙生 ...

Investment Rating - The investment rating for the CXO industry is "Outperform the Market" [1] Core Insights - The CXO index has increased by over 50% in the past year due to the easing of geopolitical risks, recovery in investment, and the digestion of high pandemic baselines [2] - Chinese CXO companies are analyzed from short-term, medium-term, and long-term perspectives to understand their global competitiveness [2] - Major players in the large molecule CDMO sector include WuXi Biologics and WuXi AppTec, with over 70% of their revenue coming from overseas [2] - The small molecule CDMO sector shows strong recovery in domestic companies, with significant order growth and a favorable competitive landscape [2] - Clinical and preclinical CROs are currently in an adjustment phase, with domestic order prices stabilizing but showing no significant recovery [2] Summary by Sections Large Molecule CDMO - Short-term performance shows high growth with competition from Japan, South Korea, and Europe [2] - Medium-term order growth is led by South Korean companies like Samsung Biologics, indicating intense competition for Chinese firms [2] - Long-term capital expenditures remain high, reflecting confidence in future demand [2] Small Molecule CDMO - Domestic companies are recovering from pandemic-related performance dips, with overall growth expected in 2025 [2] - Order growth is robust, with WuXi AppTec's orders increasing by 47% year-on-year by the end of 2024 [2] - Long-term capital expenditures show divergence, with some leaders like WuXi AppTec expected to continue increasing investments [2] Clinical/Preclinical CRO - Both domestic and international CROs are in an adjustment period, with 2022-2023 investment cooling reflected in 2024 performance [2] - Medium-term order volumes and values are beginning to show growth, while international orders remain stable [2] - Long-term capital expenditures vary among companies, indicating potential supply-demand mismatches in the short term [2] Emerging Business Opportunities - Rapid development in new molecular businesses such as peptides and oligonucleotides is expected to open up growth opportunities in the CXO sector [3] - Generic drug CROs are actively pursuing innovative transformations to seek new growth points [3]